Arno Ylitalo
Publications
- Bexmarilimab plus azacitidine for high-risk myelodysplastic syndrome and relapsed or refractory acute myeloid leukaemia: results from the dose-escalation part of a multicentre, single-arm, phase 1/2 trial (2025)
- The Lancet Haematology
(A1 Refereed original research article in a scientific journal) - CLEVER-1 targeting antibody, bexmarilimab, supports HLA-DR expression and alters ex vivo responsiveness to azacitidine and venetoclax in myeloid malignancies (2025)
- Scientific Reports
(A1 Refereed original research article in a scientific journal) - Secreted Clever-1 modulates T cell responses and impacts cancer immunotherapy efficacy (2025)
- Theranostics
(A1 Refereed original research article in a scientific journal)